Health Canada approves new kiPomalyste with Velcade and dexamethasone for treatment of adult patients with myeloma

recently announced that Health Canada has approved Pomalyste (pomalidomide, Pomadomide) and Velcade (bortezomib, bortezomib) and dexamethasone three-drug program (PVd) for adults who have previously received at least one treatment programme, including Revlimid (Lenamidi, to nale) of multiple myelomaIn May, pVd's tri-drug program was also approved by the European Commission for adult patients with multiple myeloma who have previously received at least one treatment, including RinamineAt the same time, the European Union has also approved the Revlimid joint boronzomi and dexameton three-drug program (RVd) for MM adult patients who do not meet the transplant conditions and have not received treatment in the pastAbout Pomalyst
Pomalyst is adrug(http://of immunomodulators (IMiD)The approval of the PVd tridrugscheme is based on the data of the first prospective Phase III ClinicalTrial(http://OPTIMISMMThestudy enrolled 559 MM patients who had previously received Revlimid treatment, and most (70%) had difficulty treating RevlimidAll patients have undergone 1-3 antimyeloma regimens and have progressed after the last treatmentThe results showed that the non-progressive survival of the PVd three-drug programme group was significantly extended by 4.1 months (median PFS: 11.2 months vs7.1 months;Exploratoryanalysis of patients who had previously received a treatment(http://showed a significant increase in PFS in the PVd three-drug protocol group (median PFS: 20.73 months vs 11.63 months; HR -0.54, 95% CI: 0.36-0.82), disease progression or 46% reduction in risk of death compared to the Vd two-drug protocol group